
ANI Pharma (ANIP) Stock Forecast & Price Target
ANI Pharma (ANIP) Analyst Ratings
Bulls say
ANI Pharmaceuticals is positioned for growth in the biopharmaceutical industry with a diverse portfolio of products in various therapeutic areas. The company's Rare Disease and Brands segment generate the majority of its revenues, while its Generics segment continues to expand with new product offerings. The recent 2Q 2026 earnings were above expectations, driven by strong sales in Generics and Brand Royalties and Other Revenues. Despite moderation in Cortrophin sales for 2Q 2026 and lower FY 2026 guidance, the company expects a meaningful increase in Cortrophin sales in 2H 26 and remains bullish on its longer-term outlook, supported by the expansion of its sales force and new indications for Cortrophin.
Bears say
ANI Pharmaceuticals is experiencing a decline in sales and prescription volumes for their flagship product Cortrophin Gel, leading to a decrease in revenue guidance for 2026. While the company is confident in their ability to meet the new guidance, there are risks associated with clinical, regulatory, and commercial challenges, as well as competition in the generics industry. In addition, the upcoming loss of exclusivity for their Prucalopride product could lead to a decrease in generics revenue for the company in the second quarter of 2026.
This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.
ANI Pharma (ANIP) Analyst Forecast & Price Prediction
Start investing in ANI Pharma (ANIP)
Order type
Buy in
Order amount
Est. shares
0 shares